COVID-19 Archives - BioTuesdays

Feature

Atossa Therapeutics pivots inhalation therapy from COVID-19 to oncology

With widespread availability of SARS-CoV-2 vaccines and other therapies now approved to treat COVID-19, Atossa Therapeutics (NASDAQ:ATOS) has pivoted development of its AT-H201 inhalation therapy to cancer patients with...

October 25, 2022

Developments

SAB Biotherapeutics presents new influenza and COVID-19 data

SAB Biotherapeutics (NASDAQ:SABS) presented new data at the Options for Control of Influenza conference in Belfast, showing its fully-human polyclonal antibody platform maintains its efficacy against multiple variants...

September 28, 2022

Developments

Tonix begins Phase 2 trial of TNX-102 SL in Long COVID

Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first participant in the Phase 2 PREVAIL study of TNX-102 SL as a potential treatment for a subset of patients with Long COVID syndrome whose symptoms overlap with...

August 22, 2022

Developments

iBio updates development of next-gen COVID-19 vaccine candidate

iBio (NYSEA:IBIO) provided an update on IBIO-202, its next-generation vaccine candidate under development for multi-variant COVID-19 disease. Unlike first-generation COVID vaccines that seek to provide immunity by...

August 16, 2022

Developments

PharmaJet sponsor study published in The Lancet

A Phase 3 clinical study sponsored by PharmaJet’s partner, Zydus Lifesciences, featuring ZyCoV-D, the world’s first plasmid-DNA vaccine approved for use in humans and delivered by the PharmaJet Tropis Intradermal needle...

June 8, 2022

Markets

Cantor starts Ocugen at OW; PT $4.50

Cantor Fitzgerald launched coverage of Ocugen (NASDAQ:OCGN) with an “overweight” rating and price target of $4.50. The stock closed at $2.17 on June 1. Ocugen is a clinical-stage biotechnology company focused on...

June 2, 2022

Developments

Ampio board committee conducting internal investigation

An independent special committee of the board of Ampio Pharmaceuticals (NYSE American:AMPE), with the assistance of independent legal counsel, is in the process of conducting an internal investigation that relates to...

May 17, 2022

Markets

Analysts downgrade Amarin; PTs cut to $3

Analysts for H.C. Wainwright and SVB Securities downgraded Amarin (NASDAQ:AMRN) to “neutral” from “ buy” and to “market perform” from “outperform,” respectively. Both analysts cut their prices targets to $3 from $10...

May 5, 2022

Feature

Talking mental health with Chris Wang of Shimmer

As co-founder and CEO of Shimmer, a provider of a science-backed process to reduce stress and anxiety, Chris Wang took an early interest in social impact consulting at her first job with Bain & Co. But a close family...

May 3, 2022

Developments

First Wave BioPharma fails Phase 2 GI trial to clear SARS-CoV-2

The efficacy endpoint of First Wave BioPharma’s (NASDAQ:FWBI) Phase 2 RESERVOIR trial with FW-COV did not demonstrate statistical significance, compared to placebo, in removing the SARS-CoV-2 virus from the digestive...

May 2, 2022

Tag - COVID-19

Atossa Therapeutics pivots inhalation therapy from COVID-19 to oncology

SAB Biotherapeutics presents new influenza and COVID-19 data

Tonix begins Phase 2 trial of TNX-102 SL in Long COVID

iBio updates development of next-gen COVID-19 vaccine candidate

PharmaJet sponsor study published in The Lancet

Cantor starts Ocugen at OW; PT $4.50

Ampio board committee conducting internal investigation

Analysts downgrade Amarin; PTs cut to $3

Talking mental health with Chris Wang of Shimmer

First Wave BioPharma fails Phase 2 GI trial to clear SARS-CoV-2

General

More